Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)-Reference-Cited by-同舟云学术

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

Published:2021-11 Issue: Volume:161 Page:86-93
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Saito Go,Oya Yuko,Taniguchi Yoshihiko,Kawachi Hayato,Daichi Fujimoto,Matsumoto Hirotaka,Iwasawa Shunichiro,Suzuki Hidekazu,Niitsu Takayuki,Miyauchi Eisaku,Yokoi Takashi,Yokoyama Toshihide,Uenami Takeshi,Sakata Yoshihiko,Arai Daisuke,Okada Asuka,Nagata Kenji,Teraoka Shunsuke,Kokubo Masaki

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. Cancer treatment and survivorship statistics, 2019;Miller;CA Cancer J. Clin.,2019

2. Colorectal cancer statistics, 2020;Siegel;CA: Cancer J. Clin.,2020

3. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N. Engl. J. Med.,2017

4. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N. Engl. J. Med.,2018

5. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients;Hosoya;Cancer Chemother. Pharmacol.,2019

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer;Scientific Reports;2024-08-23

2. The future of cancer treatment: combining radiotherapy with immunotherapy;Frontiers in Molecular Biosciences;2024-07-09

3. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07

4. Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005);Clinical Lung Cancer;2024-07

5. Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study;Clinical Lung Cancer;2024-07